Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $2.66, $0.15 better than the analyst estimate of $2.51. Revenue for the quarter came in at $21.4 billion versus the consensus estimate of $21.04 billion.

GUIDANCE:

Johnson & Johnson sees FY2023 EPS of $10.07-$10.13, versus the consensus of $10.03. Sees Adjusted Operational Sales up 7.2-7.7%, versus prior of 6.2-7.2%.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.